Baader Bank Aktiengesellschaft’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,277	Closed	-$5.67K	–	496
2023 Q2	$5.67K	Buy	+18,277	New	+$12.9K	﹤0.01%	386

Other funds holding CYAD

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Baader Bank Aktiengesellschaft's CYAD Position: Q3 2023 in Review

Baader Bank Aktiengesellschaft sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q3 2023, closing a stake of 18,277 shares — an estimated $5.67K sold.

Baader Bank Aktiengesellschaft first reported a position in CYAD in Q2 2023 and held it in 1 quarter. The position peaked at $5.67K in Q2 2023. 1 fund tracked by Wall St. Rank holds CYAD as of Q3 2023.

Baader Bank Aktiengesellschaft reported no remaining Celyad Oncology SA American Depositary Shares position as of Q3 2023 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 18,277 Celyad Oncology SA American Depositary Shares shares in Q3 2023, an estimated $5.67K.
Baader Bank Aktiengesellschaft first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2023 and held it in 1 quarter.
Baader Bank Aktiengesellschaft's Celyad Oncology SA American Depositary Shares position peaked at $5.67K in Q2 2023.
1 fund tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q3 2023.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q3 2023, filed 14 Nov 2023.